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Medical. Dr. DeMarcohe study sought a prospective multicenter nonrandomized evaluation of the Direct Flow Medical (DFM) system for
the treatment of severe aortic stenosis.Background The DFM transcatheter aortic valve system is a nonmetallic design with a pressurized support structure that allows
precise positioning, retrieval, and assessment of valve performance prior to permanent implantation.Methods One hundred high surgical risk patients with severe aortic stenosis were evaluated for the primary endpoint. There
were 75 patients in the group evaluable for the secondary endpoints and 25 in the pre-speciﬁed roll-in training
phase. Echocardiographic and angiographic data were evaluated by an independent core laboratory and adverse
events adjudicated by clinical event committee and classiﬁed according to Valve Academic Research Consortium
(VARC) criteria.Results There was 99% freedom from all cause mortality at 30 days (primary endpoint). VARC criteria deﬁned 30 day
combined freedom from patient safety event rate was 91% and overall device success was 93%. The post-
implantation echocardiography results demonstrated mild or no aortic regurgitation in 99% (73 of 74) with a mean
gradient of 12.6  7.1 mm Hg (n ¼ 72) and effective oriﬁce area of 1.50  0.56 cm2 and New York Heart
Association functional class was I or II in 92% of cases.Conclusions The present study demonstrates the safety and efﬁcacy of the DFM system in surgical high risk patients with severe
aortic stenosis and complex anatomy aortic regurgitation was less than moderate in 99% of patients. (J Am Coll
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764The Direct Flow Medical
(DFM) transcatheter aortic valve
system is a nonmetallic designwith
an inﬂatable and deﬂatable sup-
port structure (Fig. 1) that allows
precise positioning, retrieval and
assessment of valve performance
in its ﬁnal position. An 18-F
sheath is used for all valve sizes.The aim of this prospective multicenter study was to
determine the safety and performance of the DFM system.
Methods
Patients with symptomatic aortic stenosis who were >70
years of age were required to have a logistic Euro-
SCORE 20% or other high surgical risk features that lead
the heart team including the cardiologist and cardiovascular
surgeon at the clinical site recommend transcatheter aortic
valve replacement (TAVR). Inclusion and exclusion criteria
for all patients were reviewed by an independent patient
review committee (Online Appendix).
Severe aortic valve stenosis was deﬁned by echocardio-
graphic criteria including a mean gradient >40 mm Hg or
peak jet velocity >4.0 m/s and aortic valve area 0.8 cm2 or
aortic valve area index 0.5 cm2/m2. There was core labo-
ratory evaluation for gated cardiac computed tomography
(Clinical Imaging Analytics, Guerneville, CA) and echo-
cardiographic and angiographic studies (Medstar, Wash-
ington, DC). Aortic regurgitation was assessed according to
Valve Academic Research Consortium (VARC) criteria.
Exclusion criteria included an annulus diameter by
computed tomography scan <19 mm or >26 mm, prior to
valve surgery, prosthetic heart valve in any position, greater
than moderate mitral insufﬁciency, left ventricular ejectioncal Valve
ovine pericardial valve with an expandable Dacron poly
bular bridging system.fraction <30%, myocardial infarction or coronary interven-
tion within 30 days prior, stroke or transient ischemic at-
tack within 6 months, or chronic kidney disease (creatinine
>3.0 mg/dl).
The primary endpoint was freedom from all-cause
mortality at 30 days. Secondary endpoints included VARC-
deﬁned patient safety and device success (5). Clinical
events and safety of the study were adjudicated by inde-
pendent committees (Online Appendix). All operators
were trained on a simulated bench model and in an animal
laboratory. To allow for the operator to gain technical
expertise with this new technology, the study was designed
with a preplanned roll-in cohort of 3 patients per site.
These patients were not evaluated for secondary endpoints.
Device description. The DFM aortic valve (Fig. 1) is
a nonmetallic percutaneous bovine pericardial valve with an
expandable Dacron polyester double ring design containing
noncompliant angioplasty balloon technology. The upper
(aortic) and lower (ventricular) ring balloons, interconnected
by a tubular bridging system, can be pressurized indepen-
dently through position-ﬁll lumens. The bioprosthesis is
provided in 25 mm size for annular diameter of 19 to 24 mm
and in 27 mm size for 22 to 26 mm. Valve size recom-
mendations are based on computed tomography dimensions.
Procedure steps. All procedures were performed trans-
femorally. Following balloon valvuloplasty, the DFM
implant delivery catheter is positioned in the left ventricle
(Fig. 2). Both ring balloons are pressurized by injecting
a mixture of saline and contrast media through the position-
ﬁll lumens. Immediately, the valve is functional, without the
need for rapid ventricular pacing. The aortic ring balloon is
deﬂated. By retracting and/or pushing the 3 position wires,
the ventricular ring is aligned to the aortic annulus. The
aortic ring balloon is pressurized. The performance and
correct position are assessed. If desired, the balloons can beester double ring design. The upper (aortic) and lower (ventricular) noncompliant ring
Figure 2 DFM Delivery and Retrieval System
(A) Direct Flow Medical (DFM) valve is loaded into the delivery catheter. (B) Delivery catheter is pulled back for valve release. (C) The ring balloons and support structure are
inﬂated with a mixture of saline and contrast media. (D) For retrieval the valve is pulled into the Nitinol basket and then retrieved through the introducer sheath.
Figure 3 New York Heart Association Functional Class
Percent of patients in New York Heart Association functional class I to IV at
baseline and at 30 days.
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765depressurized and the prosthesis repositioned or completely
retrieved. For retrieval both ring balloons are deﬂated
and the valve is pulled into a Nitinol basket (Direct Flow
Medical, Santa Rosa, California) in the abdominal aorta and
retrieved through the introducer sheath. Once optimal
position is obtained, a polymer is infused into the bio-
prosthesis replacing the contrast and saline by maintaining
the pressure in the bioprosthesis at 12 atm. The polymer
solidiﬁes and the device is no longer retrievable.
Statistics. For categorical data, the denominator included
only subjects in whom the outcome could be assessed. The
p values for categorical outcomes are based on the chi-square
or Fisher’s exact test, and p values for continuous variables
were based on the 2-sample t test, unless the data showed
evidence of a signiﬁcant departure from normality in which
case theWilcoxon rank sum test was used. Results for effective
oriﬁce area, mean gradient, left ventricular ejection fraction,
and aortic regurgitation were reported from post-procedure
through 30 days by taking the ﬁrst available data point.
Results
Patient population. One hundred patients were enrolled in
9 centers in Europe (Fig. 3). Each center was allowed 3
roll-in patients. Two centers enrolled only 2 patients, and
therefore there was a total of 25 patients in the pre-speciﬁed
training cohort (cohort A). The primary endpoint of
all-cause mortality is reported for all 100 patients. All
secondary endpoints are reported for the 75 evaluablepatients (cohort B). Baseline characteristics for both cohort
A and B are shown in Table 1. There were no statistically
signiﬁcant differences between the groups.
Procedural results. Freedom from all-cause mortality at
30 days was met in 99 of 100 patients (99%). One patient
died at day 12 due to complications of pneumonia. All of the
cohort B patients underwent balloon aortic valvuloplasty
with an average of 1.5 balloon inﬂations. Balloon sizes were
Table 1 Demographics of the Roll-In Patients (Cohort A) and the Evaluable Patients (Cohort B)
Training Cohort Evaluable Cohort
p ValueN N
Characteristic
Age, yrs 25 83.2  6.7, 63–95 75 83  5.7, 65–94 0.88
Male 25 48% (12) 75 50.7% (38) 0.82
STS score 23 9.9  8.9, 3.6–40.1 67 9.7  8.8, 0.3–54 0.82*
Logistic EuroSCORE 25 21.8  10.9, 3.5–46.1 74 22.8  11.5, 1.9–55.3 0.69
NYHA functional class II 25 32% (8) 75 40% (30) 0.48
NYHA functional class III or IV 25 68% (17) 75 54.7% (41) 0.24
Coronary artery disease 25 56% (14) 73 58.9% (43) 0.80
Previous MI >30 days 25 8% (2) 75 9.3% (7) >0.99
Previous CABG 25 24% (6) 75 22.7% (17) 0.89
Previous PTCA 25 28% (7) 74 32.4% (24) 0.68
Previous stroke/TIA (within 6 months) 25 0% (0) 75 0% (0) n/a
Peripheral arterial disease 24 16.7% (4) 74 25.7% (19) 0.37
Chronic lung disease (FEV1 <1) 23 13% (3) 75 12% (9) >0.99
Chronic renal insufﬁciency 25 32% (8) 75 24% (18) 0.43
Atrial ﬁbrillation/ﬂutter 25 20% (5) 75 33.3% (25) 0.21
Previous pacemaker implant 25 8% (2) 75 14.7% (11) 0.51
Hypertension 25 76% (19) 75 85.3% (64) 0.36
Congestive heart failure 25 40% (10) 75 42.7% (32) >0.99
Comorbidities deeming nonoperable
Severe COPD 25 24% (6) 70 10% (7) 0.10
Porcelain aorta 25 0% (0) 70 8.6% (6) 0.34
Previous thorax irradiation 25 0% (0) 70 0% (0) n/a
Other 25 92% (23) 70 88.6% (62) >0.99
Echocardiographic ﬁndings
Aortic valve area, cm2 15 0.4  0.1, 0.2–0.4 56 0.4  0.1, 0.2–0.6 0.80
Mean aortic valve gradient, mm Hg 22 44.4  10 65 44.1  9.6 0.92
Mean LVEF 17 58.2  4.8 51 56.1  9.9 0.90*
Moderate or severe mitral regurgitation 21 4.8% (1) 64 6.3% (4) >0.99
Mean annulus diameter, 25-mm valve 13 22.6  1 45 22.9  1.3 0.50
Mean annulus diameter, 27-mm valve 11 25.3  1, 24–27.1 28 24.9  1.1, 22.1–26.5 0.32
Values are mean  SD, range, or % (n). *p Value is based on the nonparametric Wilcoxon rank sum test due to signiﬁcant departures from normality.
CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second. LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction;
NYHA ¼ New York Heart Association functional class; PTCA ¼ percutaneous transluminal coronary angioplasty; STS ¼ Society of Thoracic Surgeons; TIA ¼ transient ischemic attack.
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76623 mm for the 25 mm and 25 mm for the 27 mm valve.
Seventy-four of 75 patients received the study device,
44 patients a 25 mm, and 30 a 27-mm valve. No patient
required post-implant balloon dilation.
The average time from sheath insertion to vessel closure
was 37.6 min including the time to position and assessTable 2 VARC-Deﬁned Device Success
Device Success Component Result
Successful vascular access, delivery, and deployment
of the device and successful retrieval of the delivery system
99% (74/75)
Correct position of the device in the proper
anatomical location
99% (74/75)
Intended performance of the prosthetic heart valve mean
aortic valve gradient <20 mm Hg or peak velocity <3 m/s,
without moderate or severe prosthetic valve AR*
93% (71/74)
Only 1 valve implanted 100% (75/75)
Combined device success 93% (70/75)
Values are % (n/N). *Because of the difﬁculty in adequate echocardiographic images for core lab
analysis of aortic valve area, the device success is evaluated without the aortic valve area criteria.
VARC ¼ Valve Academic Research Consortium.valve function, which was on average 14 min. This included
transesophageal echocardiography, invasive hemodynamics,
and angiography. The recommended minimal arterial
access size was >6.5 mm and the minimum diameter
accessed was 5.2 mm. Based on investigator preference, 15
patients (20%) had surgical femoral cut-down and 60 (80%)
percutaneous arterial closure. New York Heart Association
functional class improved by at least 1 in 83%, at least 2 in
34%, and 3 in 1.5% of patients.
VARC-deﬁned device success. VARC-deﬁned device
success was obtained in 93% (70 of 75 patients) (Table 2).
Device failure was due to a post-implant transvalvular
gradient 20 mm Hg or peak velocity 3 m/s in 2 patients.
One patient (1.4%) had moderate aortic regurgitation. Eight
patients required retrieval of the initially attempted valve
implant that was successful in all cases. Six retrievals were
done to place a different size valve and 2 were due to
retraction of the valve into the aorta during attempted
placement. In all patients, another DFM valve was success-
fully implanted.
Table 3 VARC-Deﬁned Safety at 30 Days (N ¼ 75)
Component Result
All-cause mortality 1.3% (1)
Major stroke 4% (3)
Life-threatening or disabling bleeding 2.7% (2)
Stage 3 acute kidney injury 0% (0)
Periprocedural myocardial infarction 1.3% (1)
Major vascular complications 2.7% (2)
Repeat procedure for valve-related dysfunction 1.3% (1)
Combined safety endpoint
freedom from event (per patient)
91% (68/75)
Values are % (n) or % (n/N).
VARC ¼ Valve Academic Research Consortium.
Table 5 Aortic Regurgitation by Echocardiography
Post-Procedure (Echo)
(Through 30 Days)
Transvalvular (central) regurgitation VARC
None 90.5% (67/74)
Mild 9.5% (7/74)
Moderate 0% (0/74)
Severe 0% (0/74)
Paravalvular regurgitation VARC
None 70.3% (52/74)
Mild 28.4% (21/74)
Moderate 1.4% (1/74)
Severe 0% (0/74)
Total aortic regurgitation VARC
None 62.2% (46/74)
Mild 36.5% (27/74)
Moderate 1.4% (1/74)
Severe 0% (0/74)
Values are % (n/N).
Echo ¼ echocardiography; VARC ¼ Valve Academic Research Consortium.
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767VARC-deﬁned patient safety at 30 days. The 30-day
freedom from event rate was 91% (68 of 75 patients)
(Table 3). Major strokes occurred in 3, at days 1, 2, and 19
after the procedure. The third had chronic atrial ﬁbrillation
without oral anticoagulation. The composite of stroke and
death within 30 days occurred in 3 patients. Two patients
had life-threatening or disabling bleeding due to femoral
arterial access site bleeding and retroperitoneal hematoma.
VARC-deﬁned major vascular complications occurred in 2:
retroperitoneal hematoma and closure device failure re-
quiring surgical repair. Periprocedural myocardial infarction
occurred in 1 patient. An acute conversion to surgical aortic
valve replacement was performed in 1 patient due to im-
proper initial placement of the valve. The patient had an
uneventful postoperative recovery. The rate of pacemaker
implantation for all 100 patients was 17%.
Echocardiographic transvalvular gradient. The mean
gradient decreased from an average of 45.9  9.6 mm Hg
(n ¼ 72) to an average of 12.6  7.1 mm Hg (n ¼ 72) post-
procedure through 30 days (Table 4). The effective oriﬁce
area at baseline was 0.65  0.18 cm2 (n ¼ 60) and increased
to 1.50  0.56 cm2 (n ¼ 64) at 30 days.
Aortic regurgitation. The post implantation VARC-
deﬁned aortic regurgitation was mild or less in 73 of 74
(98.6%) No patient had severe aortic regurgitation (Table 5).
The severity of central aortic regurgitation was graded as
none or mild in all 74 patients. Paravalvular regurgitation wasTable 4
Pre- and Post-Echocardiographic Data (Mean Gradient,
Effective Oriﬁce Area, LV Ejection Fraction)
Baseline
Post-Procedure
(Through 30 Days)
Mean gradient, mm Hg 45.9  9.6
27.9–68.9
(n ¼ 72)
12.6  7.1
0.8–38.4
(n ¼ 72)
Effective oriﬁce area, cm2 0.65  0.18
0.28–1.11
(n ¼ 60)
1.50  0.56
0.58–3.59
(n ¼ 64)
LVEF, % 56.1  9.9
27.7–70.0
(n ¼ 51)
56.3  9.5
32.0–73.0
(n ¼ 60)
Values are mean  SD and min–max range.
LVEF ¼ left ventricular ejection fraction.none in 70.3%, mild in 28.4%, and moderate in 1 (1.4%)
(Fig. 4). Aortic regurgitation could be evaluated by contrast
aortography immediately post implant in 63 patients.
According to American College of Cardiology/American
Heart Association criteria (6), it was mild or less in 62 (97%)
and moderate in 2 (3%).Discussion
The major ﬁndings of this multicenter nonrandomized study
of the DFM 18-F system for high surgical risk patients with
severe aortic stenosis were a VARC-deﬁned device success
rate of 93% and 30-day freedom from VARC-deﬁned safety
event rate of 91%with an all-causemortality rate of 1.0% (1 of
100) at 30 days. These results compare favorably to a recent
meta-analysis of 16 studies including 3,519 patients usingFigure 4 Paravalvular Aortic Regurgitation
Percent of patients with different grades of paravalvular aortic regurgitation
through 30 days according to echocardiographic Valve Academic Research
Consortium criteria.
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768both Edwards (Edwards Lifesciences, Irvine, California) and
CoreValve (CoreValve Medtronic, Minneapolis, Minnesota)
prosthesis (7–9). In this analysis, combined device success
was 92%, 30-day event rate was 22.1%, and 30-day mortality
was 7.8%, stroke was 5.7%, vascular complications was
18.8%, new pacemaker was 13.9%, and the combined inci-
dence of valve embolization or need for open surgery was
3.0%. Similar rates were reported in other studies (1–3,8).
Aortic regurgitation. Post implantation aortic regurgita-
tion, using VARC criteria, was none in 62.2%, mild in
36.5%, and moderate in 1.4% of patients. No patients had
severe aortic regurgitation. The device has conformable rings
and is retrievable if the size of the prosthesis is incorrect,
which is a frequent reason for signiﬁcant paravalvular
regurgitation. In contrast to the DFM valve, results obtained
with the SAPIEN and CoreValve show incidences of
moderate to severe AR ranging from 12% to 21%, respec-
tively (7,8). The importance of this ﬁnding is reﬂected in the
higher incidence of death in those with residual moderate or
greater AR compared to those without.
Stroke rate. The PARTNER trial demonstrated that neu-
rologic events occurred more frequently after TAVR than
surgical aortic valve replacement at 30 days and 1 year (10). In
the present study, the incidence of stroke was 4% (n¼ 3). One
of the 3 patients with stroke after 3 weeks had atrial ﬁbrillation
without oral anticoagulation at the time of the event. Nuis et al
evaluated the frequency and causes of stroke with TAVR
in 214 patients (11). Stroke occurred in 19 patients (9%).
Independent determinants of stroke were new-onset atrial
ﬁbrillation and baseline aortic regurgitation grade 3.
Vascular and bleeding complications. The low proﬁle and
high degree of ﬂexibility and trackability of the delivery
catheter lead to low major vascular and life threatening or
disabling bleeding complications. They were both 2.7%. In
the PARTNER (Placement of AoRTic TraNscathetER
Valve Trial) trial (12), major vascular complications and
major bleeding after transfemoral TAVR were seen in 15.3%
and 60.9%, respectively. Major vascular complications were
associated with a more than 4-fold increase in 30-day
mortality and a high rate of major bleeding (60.9%) at 30
days, and were an independent predictor of 1-year mortality.
New pacemaker implantations. The incidence of a new
permanent pacemaker range from 24% to 29% in those
receiving CoreValve and 5% to 11% with SAPIEN (8,9,13).
The overall permanent pacing rate for all patients in this
study was 17%.
Study limitations. Themain limitations of this study are the
small cohort and the limited follow-up duration. Core labo-
ratory analyzable images were not available for all patients.
Conclusions
The present study demonstrates the safety and efﬁcacy of the
repositionable, retrievable DFM System in high and extremerisk patients with severe aortic stenosis. Less than moderate
aortic regurgitation occurred in 99% of patients.
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